Catalyst Event
AbbVie Inc (ABBV) · Other
From KEDI U.S. Dividend100 90% Participation + Daily Options Premium Index (KUSDV100P)
3/18/2026, 12:00:00 AM
AbbVie's stock price declined on March 18, 2026, following FDA approvals in early March for competitor immunology drugs from Johnson & Johnson (ICOTYDE) and Bristol Myers Squibb (Sotyktu), increasing competition for AbbVie's products.
Korean Translation
2026년 3월 18일, 3월 초 존슨앤드존슨(ICOTYDE) 및 브리스톨 마이어스 스큅(Sotyktu)의 경쟁 면역학 약물에 대한 FDA 승인 이후 애브비의 주가 하락 및 경쟁 심화됨.
Related Recent Events
Murphy Oil Corp (MUR) · Earnings Release
The company is expected to release its Q1 2026 earnings results on or around May 6, 2026, scheduled.
5/6/2026, 12:00:00 AM
Sysco Corporation (SYY) · Earnings Release
Sysco's Q3 2026 earnings release is expected on or around May 5, 2026, based on past reporting schedules. Analysts forecast an EPS of $0.95. High importance is estimated due to historical price volatility following earnings. This is scheduled.
5/5/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Earnings Release
Merck & Co. is expected to release its Q1 2026 earnings results on or around April 30, 2026, before the market opens. High impact expected as earnings releases often drive price movements exceeding 10%, scheduled.
4/30/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Other
The FDA has set a PDUFA target action date of April 28, 2026, for its review of the New Drug Application for doravirine/islatravir, an investigational HIV treatment. Approval typically impacts price by 5-10%, scheduled.
4/28/2026, 12:00:00 AM
United Parcel Service Inc (UPS) · Earnings Release
UPS Q1 2026 earnings release and conference call scheduled.
4/28/2026, 12:00:00 AM
Coca-Cola Co (The) (KO) · Earnings Release
First quarter 2026 earnings release on April 27, 2026, for which low importance is estimated due to typical market reaction to quarterly results, is scheduled.
4/27/2026, 12:00:00 AM